BMS & Pfizer further impress with full ARISTOTLE data on blood thinner Eliquis
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Pfizer have reported full data from the ARISTOTLE study of their anticoagulant Eliquis (apixaban) in preventing stroke in patients with atrial fibrillation (AF), and the data have only further impressed analysts, leading some to peg the drug as potentially taking "best-in-class".